Program
TQF3250
A development code. Also written as “TQF3250 capsules” and “TQF3250 capsule”.
In Sino Biopharmaceutical's pipeline, GLP-1R激动剂 (口服)
. Its studies are mostly in Obesity · Hyperglycemia, led by Sino Biopharmaceutical.
Furthest: phase 1, since Dec 5, 20253 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 33 open or running | phase 1since Dec 5, 2025 | Dec 5, 2025 | Dec 2026phase 1 · NCT07327281 |
- Named in Sino Biopharmaceutical’s own pipeline as
TQF3250
, phase 1, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 5, 2025First study: phase 1 study in HyperglycemiaFirst studyNCT07327281 · 66 planned · China
- Jul 30, 2026Phase 1 study in ObesityNCT07747857 · 72 planned · China
- Aug 27, 2026Phase 1 study in OverweightNCT07798284 · 80 planned · China
Ahead
- Dec 2026Primary completion: phase 1 study in HyperglycemiaNCT07327281
- Apr 2027Primary completion: phase 1 study in OverweightNCT07798284
- Jun 2027Primary completion: phase 1 study in ObesityNCT07747857
TargetBeta
“GLP-1R激动剂 (口服)”the company's pipeline, read by Claude · source
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07798284Overweight · China | 1 | Recruiting | Apr 2027 | 80 |
| NCT07747857Obesity · China | 1 | Recruiting | Jun 2027 | 72 |
| NCT07327281Hyperglycemia · China | 1 | Recruiting | Dec 2026 | 66 |
How it is read
Names in the registry
- “TQF3250 capsules”, 2 entries
- “TQF3250 capsule”, 1 entry
Codes read as this program: TQF3250.
Conditions, from the studies’ own filings
- Obesity, 2 studies
- Hyperglycemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.